Literature DB >> 16953269

Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.

Lysiane Hilbert1, Paquita Nurden, Claudine Caron, Alan T Nurden, Jenny Goudemand, Dominique Meyer, Edith Fressinaud, Claudine Mazurier.   

Abstract

Type 2N von Willebrand disease (VWD) is characterized by a markedly decreased affinity of von Willebrand factor (VWF) for factorVIII (FVIII) and is caused by mutations in the D' or D3 domain of mature VWF. We now report a French patient with an atypical 2N VWD phenotype associating FVIII deficiency with plasmaVWF unable to bind FVIII (undetectableVWF:FVIIIB) but with an abnormal multimeric profile. This patient is heterozygous for both the frequent R854Q type 2NVWD mutation and a novel R763G mutation at the cleavage site between VWF propeptide and mature VWF. Four children of the patient displayed moderately decreased VWF:FVIIIB of plasma VWF and were heterozygous for either the R763G or the R854Q mutation. Children with the R763G mutation displayed the same abnormal multimeric profile as their father. Recombinant VWF (rVWF) expression studies performed in COS-7 cells showed that the R763G mutation subtly affects its multimeric profile and dramatically impairs its FVIII binding function. Furthermore, the characteristics of hybrid G763/Q854 rVWF resulting from cotransfection experiments were in agreement with the type 2N VWD diagnosis of the patient. We conclude that R763G is a new type 2N VWD mutation located in the VWF propeptide which alters the proteolytic processing of VWF and consequently its binding to FVIII.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953269     DOI: 10.1160/TH06-03-0157

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 3.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

Review 4.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

5.  [The function and clinical value of Von Willebrand factor propeptide].

Authors:  Jie Yin; Changgeng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

6.  Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Authors:  Nina Borràs; Javier Batlle; Almudena Pérez-Rodríguez; María Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Ignacia Balda; Carme Altisent; Rocío Pérez-Montes; Rosa María Fisac; Gemma Iruín; Sonia Herrero; Inmaculada Soto; Beatriz de Rueda; Víctor Jiménez-Yuste; Nieves Alonso; Dolores Vilariño; Olga Arija; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Lizheidy Sarmiento; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María César; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Rosa Cornudella; Carlos Aguilar; Francisco Vidal; Irene Corrales
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.